Liraglutide
Also known as: Saxenda, Victoza, GLP-1 analogue, GLP-1 receptor agonist, incretin mimetic
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist
What it is
Liraglutide is the active ingredient in Victoza (type 2 diabetes) and Saxenda (obesity), FDA-approved drugs for blood sugar control and weight loss. It works by mimicking a gut hormone to curb appetite and regulate insulin. Prescription only; also studied for cardiovascular protection and fatty liver disease.
The scientific side
Liraglutide is an acylated glucagon-like peptide-1 (GLP-1) analogue with 97% amino acid homology to native GLP-1. It acts as a GLP-1 receptor agonist, binding to the GLP-1 receptor to improve fasting and postprandial glycaemic control via glucose-dependent increases in insulin secretion and reductions in glucagon levels, with minor delays in gastric emptying. Liraglutide also reduces appetite and energy intake, and has effects on postprandial lipid profiles. Its prolonged action (half-life approximately 13 hours) is attributable to slowed release from the injection site, reduced elimination via metabolic stabilisation, and reduced renal filtration, enabling once-daily dosing. Beyond glycaemic effects, liraglutide activates HCN channels in pancreatic islets to augment calcium oscillation frequency and insulin secretion, inhibits NF-κB phosphorylation, activates AMPK to enhance lipophagy, modulates macrophage polarization via PI3K/AKT and STAT3/6 pathways, promotes neuroplasticity and reduces neuroinflammation, and exerts antioxidant and anti-apoptotic effects.
Class: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist
Legal & regulatory status
Approved for treatment of type 2 diabetes and obesity (cited as approved for weight management under brand name Saxenda, and for T2DM; PMID: 26074046, 28701318). Specific approval dates and full label indications…
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
What it's studied for
- Type 2 diabetes mellitus — glycaemic control Human RCT
- Liraglutide administered by subcutaneous injection once daily improves fasting and postprandial glycaemic control via increased insulin and reduced glucagon levels; widely used for T2DM treatment. PMID 26597252 Jacobsen LV et al. Clinical pharmacokinetics (2016)
- Once-daily liraglutide 1.2 mg vs once-weekly semaglutide 1.0 mg in T2DM: liraglutide reduced HbA1c by 1.0% from baseline of 8.2% and body weight by 1.9 kg over 30 weeks. Semaglutide was superior on both endpoints. PMID 31539622 Capehorn MS et al. Diabetes & metabolism (2020) — SUSTAIN 10
- In adults with type 1 diabetes, liraglutide 1.8 mg and 1.2 mg added to insulin reduced HbA1c by 0.34–0.54% from mean baseline 8.2%; also reduced insulin dose and body weight. However, symptomatic hypoglycaemia and hyperglycaemia with ketosis increased, limiting clinical use. PMID 27506222 Mathieu C et al. Diabetes care (2016) — ADJUNCT ONE
- Obesity and overweight — weight management Human RCT
- Subcutaneous liraglutide 3 mg once daily indicated as adjunct to reduced-calorie diet and physical activity for chronic bodyweight management in adults with BMI ≥30 or ≥27 with comorbidity; phase III trials (32–56 weeks) showed clinically relevant reductions in bodyweight. PMID 25985864 Scott LJ. Drugs (2015)
- Liraglutide 3.0 mg daily approved by FDA and EMA for weight management; 56 weeks of treatment produced 5.9–8.0% weight reduction; placebo-subtracted weight loss 3.9–6.0%; 50–76% of patients achieved ≥5% weight loss. PMID 26074046 Christou GA et al. Current vascular pharmacology (2016)
- Systematic review of 15 RCTs (960 participants): liraglutide significantly reduced total weight, fat mass, and visceral adipose tissue (VAT 12.49–23%) vs placebo. PMID 39904668 Schmidt PHS et al. Obesity research & clinical practice (2025)
- Bayesian NMA in non-T2DM obesity/overweight: all tirzepatide doses showed greater weight reduction vs liraglutide; all interventions had comparable safety profiles. PMID 41820778 Ciudin A et al. Advances in therapy (2026) — NMA
- Cardiovascular outcomes in type 2 diabetes — MACE reduction Human RCT
- LEADER trial (9,340 patients, advanced T2DM, high CV risk, median 3.8-year follow-up): liraglutide significantly reduced composite of CV death, non-fatal MI, non-fatal stroke (HR 0.87; 95% CI 0.78–0.97); CV death HR 0.78 (95% CI 0.66–0.93); all-cause death HR 0.85 (95% CI 0.74–0.97). Nephropathy events also significant PMID 29737256 Mikhail N. Current hypertension reviews (2019)
- LEADER trial showed liraglutide to be the second modern glucose-lowering agent to demonstrate significant CV benefit; whether benefits extend beyond high-CV-risk T2DM populations remains unclear. PMID 28387138 Chudleigh RA, Bain S. Expert opinion on drug safety (2017)
- In LEADER, liraglutide reduced CV mortality, total mortality, non-fatal MI and stroke composite; no effect on heart failure; reduces progression of diabetic kidney disease. PMID 31055989 Madsbad S. Expert review of cardiovascular therapy (2019)
- Blood pressure reduction Human RCT
- Meta-analysis of 10 RCTs (968 T2DM patients): liraglutide 1.8 mg/day reduced SBP by 5.39 mmHg (95% CI −7.26, −3.51); no significant effect on DBP; heart rate increased by 6.03 bpm. PMID 31610701 Zhao D et al. Clinical and experimental hypertension (2020)
- Meta-analysis of 18 RCTs (7,616 liraglutide, 6,046 control): liraglutide reduced SBP by 3.18 mmHg (95% CI −4.32, −2.05); SBP reduction dose-dependent but not significant beyond 1 year; liraglutide 3.0 mg/d significantly reduced DBP; 1.8 mg/d slightly increased DBP. PMID 30616638 Zhao X et al. BMC endocrine disorders (2019)
- Visceral and ectopic fat reduction Human RCT
- Meta-analysis of 16 RCTs (845 participants): liraglutide significantly reduced visceral fat (SMD −0.72), liver fat (SMD −0.78), and BMI vs control; adequate dosage (≥1.8 mg/day) and duration (16–40 weeks) were decisive factors; main adverse event was mild gastrointestinal reactions. PMID 36314246 He F et al. Diabetes, obesity & metabolism (2023)
- Peripheral artery disease — peripheral perfusion improvement in T2DM Human RCT
- 18-month RCT in 55 T2DM patients with PAD: liraglutide up to 1.8 mg/day significantly improved transcutaneous oxygen pressure vs control (ETD 10.9 mmHg, p<0.001); reduced urine albumin-to-creatinine ratio, CRP, and IL-6; increased circulating and endothelial progenitor cells and VEGF-A. PMID 40276845 Caruso P et al. Diabetes, obesity & metabolism (2025) — STARDUST trial
- Polycystic ovary syndrome (PCOS) — metabolic and reproductive outcomes Mixed
- Double-blind RCT (72 PCOS women): liraglutide 1.8 mg/day for 26 weeks caused 5.2 kg weight loss vs placebo; improved bleeding ratio, increased SHBG, reduced free testosterone; nausea and constipation more prevalent with liraglutide. PMID 28479118 Nylander M et al. Reproductive biomedicine online (2017)
- Meta-analysis of 12 RCTs (1,096 PCOS patients): liraglutide + metformin superior to metformin alone for BMI, glucose, lipids, hormone levels, menstrual cycles, ovulation rate, and spontaneous conception; higher gastrointestinal adverse event incidence with combination. PMID 40481408 Huang R, He Y. BMC women's health (2025)
- Liraglutide inhibits CXCL10 secretion in PCOS granulosa cells via JAK signaling pathway, improving follicle development and ovulation in DHEA-induced mouse model and human granulosa cells. PMID 39107809 Zhao M et al. Reproductive biology and endocrinology (2024)
- Obstructive sleep apnea — AHI reduction Human RCT
- Randomized double-blind 32-week trial (359 non-diabetic obese participants with moderate/severe OSA): liraglutide 3.0 mg reduced AHI by −12.2 vs −6.1 events/h with placebo (ETD −6.1 events/h, P=0.015); produced 5.7% vs 1.6% weight loss; greater reductions in HbA1c and SBP. PMID 27005405 Blackman A et al. International journal of obesity (2016) — SCALE Sleep Apnea
- Weight management after bariatric surgery failure Human observational
- Retrospective multicenter cohort (119 patients with insufficient weight loss or weight regain after bariatric surgery): liraglutide 3 mg produced 5.6% weight loss at 12 weeks and 9.3% at 24 weeks; meta-analysis showed body weight reduction of 7.9 kg (95% CI −10.4 to −5.4); no serious side effects reported. PMID 38183597 Vinciguerra F et al. Obesity surgery (2024)
- Prediabetes — weight and metabolic management Human RCT
- Meta-analysis of 5 RCTs (1,604 liraglutide, 859 control in prediabetes): liraglutide reduced body weight (MD −4.95 kg), BMI (−2.06 kg/m²), waist circumference (−4.61 cm), HbA1c (−0.33%), and LDL cholesterol (−0.36 mmol/L); adverse event rate higher with liraglutide. PMID 38782201 Alsanea S et al. Endocrine practice (2024)
- Pediatric obesity — weight management in children and adolescents Human RCT
- Meta-analysis of 7 RCTs (547 children/adolescents): liraglutide reduced body weight (WMD −2.13 kg), BMI (WMD −1.56 kg/m²), BMI SDS (WMD −0.17), HbA1c (WMD −0.29%), and fasting plasma glucose; no significant difference in adverse event frequencies vs placebo. PMID 37672063 Gou H et al. European journal of pediatrics (2023)
- Population PK/PD analysis: body weight was the main covariate affecting liraglutide exposure (lower exposures at higher body weights); similar exposures in adolescents and adults; exposure-response relationship demonstrated for BMI SDS reduction. PMID 33963681 Carlsson Petri KC et al. Pediatric obesity (2021)
- Diabetic kidney disease / nephropathy Human RCT
- Meta-analysis of 18 RCTs (1,580 T2DN patients): liraglutide reduced UACR, serum creatinine, cystatin C, blood glucose (FBG, PBG, HbA1c), BMI, TNF-α, and IL-6; no significant difference in BUN or eGFR. PMID 35392872 Mali N et al. BMC endocrine disorders (2022)
- Non-alcoholic fatty liver disease (NAFLD) Human RCT
- Meta-analysis of 5 RCTs (371 participants): liraglutide produced non-significant decrease in hepatic fat content and ALT; significantly reduced BMI (driven by T2DM subgroup) and triglycerides; increased gastrointestinal adverse events. Authors did not substantiate routine use in NAFLD. PMID 33309563 Kalogirou MS et al. Clinics and research in hepatology and gastroenterology (2021)
- Stable bipolar disorder with obesity — weight and binge eating Human RCT
- 40-week double-blind RCT (60 participants with stable bipolar disorder, obese/overweight): liraglutide 3 mg/day vs placebo — significantly greater weight reduction, more participants losing ≥5% body weight, reductions in BMI, HbA1c, binge eating, and hunger; well tolerated with minimal neuropsychiatric adverse effects. PMID 38227621 McElroy SL et al. Journal of clinical psychopharmacology (2024)
- Depressive symptoms — potential psychiatric application Mixed
- Review: liraglutide modulates mood-related neural circuits, neuroplasticity, synaptic remodeling, and neuroinflammatory processes; preclinical and early-phase clinical insights suggest benefit for depressive symptoms; evidence remains preliminary. PMID 40471368 Gammoh O et al. Molecular biology reports (2025)
- Diabetic wound healing Animal studies only
- In diabetic mouse models (db/db and STZ-induced): liraglutide significantly accelerated wound closure by improving re-epithelialization, collagen deposition, ECM remodeling, and keratinocyte function via Myo1c/Dock5 pathway; effects abrogated in Dock5 keratinocyte-specific knockout mice. PMID 39159301 Zhang Q et al. Advanced science (2024)
- Intrauterine adhesion — anti-fibrotic/anti-inflammatory effect Animal studies only
- In IUA rat models and human endometrial organoid models: liraglutide reduced endometrial inflammation, collagen fibrosis, and EMT by directly targeting and inhibiting NF-κB phosphorylation. PMID 40784419 Shi J et al. Experimental cell research (2025)
- Aortic aneurysm and dissection — protective effects Animal studies only
- In APOE−/− mice with Ang II-induced AAD: liraglutide (200 µg/kg i.p.) significantly reduced AAD incidence and mortality; inhibited M1 macrophage polarization via GLP-1R/PI3K/AKT pathway; suppressed CXCL3 expression. PMID 38548245 Zhang K et al. Biochemical pharmacology (2024)
- Hepatic steatosis — lipid accumulation reduction Animal studies only
- In HFD-fed mice and palmitic-acid-treated hepatocytes: liraglutide alleviated liver steatosis via RORα-mediated autophagic pathway; effect lost in liver-specific Rorα knockout mice. PMID 37310057 Yu X et al. IUBMB life (2023)
- Renal ischemia-reperfusion injury — renoprotection Animal studies only
- In C57BL/6J mice with RIRI: liraglutide relieved RIRI and ferroptosis, inhibited macrophage extracellular trap formation, and skewed macrophage polarization to M2 phenotype via STAT3/6 pathway. PMID 39340991 Sun Z et al. International immunopharmacology (2024)
- Diabetic cardiomyopathy — cardioprotection Mixed
- Review: liraglutide demonstrated antioxidant, antihyperglycemic, anti-apoptotic, and anti-inflammatory actions in preclinical and clinical studies of diabetic cardiomyopathy. PMID 37966282 Gupta P, Ekbbal R. Current drug research reviews (2024)
- Age-related macular degeneration — RPE cytoprotection In vitro only
- In ARPE-19 cells: liraglutide activated AMPK, reduced lipid droplet accumulation, mitigated oxidative stress, suppressed EMT, and influenced exosome secretion; foundational in vitro evidence for GLP-1RA use in AMD. PMID 40332323 Tsou SH et al. International journal of molecular sciences (2025)
- Neuroprotection — Alzheimer's disease and cerebral ischemia Animal studies only
- Review of preclinical data: liraglutide reduced ischemia area caused by MCAO, limited neurological deficits, exerted anti-apoptotic effects (↑Bcl-2/Bcl-xl, ↓Bax/Bad), reduced NF-κB, ICAM-1, caspase-3, and free radicals; potential effects on Aβ clearance and tau pathology in Alzheimer's disease models. PMID 30823403 Wiciński M et al. International journal of molecular sciences (2019)
- Opioid use disorder — reduction of heroin/fentanyl seeking in preclinical models Animal studies only
- In male rats: subcutaneous liraglutide (0.06–0.60 mg/kg) dose-dependently decreased wakefulness and increased NREM sleep at doses that also reduce heroin and fentanyl seeking; body weight decreased as expected. PMID 36410565 Fang J et al. Brain research bulletin (2023)
Protocol
0.6 mg subcutaneous injection, once daily. Cycle: 1 week.
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| subcutaneous injection | 1.2 mg once daily | 30 weeks | human | Research PMID 31539622 |
| subcutaneous injection | 0.6 mg, 1.2 mg, or 1.8 mg once daily | 52 weeks | human | Research PMID 27506222 |
| subcutaneous injection | 1.8 mg once daily | 26 weeks | human | Research PMID 28479118 |
| subcutaneous injection | up to 1.8 mg once daily | 18 months | human | Research PMID 40276845 |
| subcutaneous injection | 1.8 mg once daily | 16 ± 9 weeks (mean across 10 trials) | human | Research PMID 31610701 |
| subcutaneous injection | 3.0 mg once daily | 32 weeks | human | Research PMID 27005405 |
| subcutaneous injection | 3.0 mg once daily | 32–56 weeks (phase III trials) | human | Research PMID 25985864 |
| subcutaneous injection | 3.0 mg once daily (target dose, titrated) | 40 weeks | human | Research PMID 38227621 |
| subcutaneous injection | 3.0 mg | up to 24 weeks | human | Research PMID 38183597 |
| subcutaneous injection | ≥1.8 mg/day (adequate dose per subgroup analysis) | 16–40 weeks (adequate duration per subgroup analysis) | human | Research PMID 36314246 |
| intraperitoneal injection | 200 µg/kg intraperitoneally | Not specified | animal | Research PMID 38548245 |
| Not specified (animal study) | 0.4 mg/kg per day | Not specified | animal | Research PMID 39154828 |
| intraperitoneal injection | 200 µg/kg/day intraperitoneally | 5 weeks | animal | Research PMID 35311455 |
| subcutaneous injection | 0.06, 0.10, 0.30, or 0.60 mg/kg | Single doses, within-subjects design | animal | Research PMID 36410565 |
| subcutaneous injection | 0.6 mg | once daily · 1 week | biohackers and off-label users initiating liraglutide for weight loss | [Community] |
| subcutaneous injection | 1.2 mg | once daily · 1 week | biohackers and off-label users titrating liraglutide for weight loss or glycemic control | [Community] |
| subcutaneous injection | 1.8 mg | once daily · ongoing (weeks to months) | biohackers, overweight/obese adults pursuing off-label weight loss, and type 2 diabetes management users | [Community] |
| subcutaneous injection | 2.4 mg | once daily · ongoing (weeks to months) | biohackers pursuing aggressive weight loss, users who tolerated 1.8 mg well and seek further appetite suppression | [Community] |
| subcutaneous injection | 3.0 mg | once daily · ongoing (weeks to months) | biohackers and off-label users pursuing maximum weight loss effect with liraglutide | [Community] |
| subcutaneous injection | 0.6 mg | once daily · 2–4 weeks (extended low-dose protocol) | GLP-1-naive users, peptide biohackers sensitive to GI side effects, older adults | [Community] |
| subcutaneous injection | 1.2 mg | once daily · ongoing (maintenance) | biohackers managing type 2 diabetes or mild insulin resistance off-label; users who achieve sufficient appetite suppression at sub-maximum doses | [Community] |
All studies (38)
- PMID 25985864 Human RCT
Obesity and overweight — weight management - PMID 26074046 Human RCT
Obesity and overweight — weight management - PMID 26597252 Human RCT
Type 2 diabetes mellitus — glycaemic control - PMID 27005405 Human RCT
Obstructive sleep apnea — AHI reduction - PMID 27506222 Human RCT
Type 2 diabetes mellitus — glycaemic control - PMID 28387138 Human RCT
Cardiovascular outcomes in type 2 diabetes — MACE reduction - PMID 29737256 Human RCT
Cardiovascular outcomes in type 2 diabetes — MACE reduction - PMID 30616638 Human RCT
Blood pressure reduction - PMID 31055989 Human RCT
Cardiovascular outcomes in type 2 diabetes — MACE reduction - PMID 31539622 Human RCT
Type 2 diabetes mellitus — glycaemic control - PMID 31610701 Human RCT
Blood pressure reduction - PMID 33309563 Human RCT
Non-alcoholic fatty liver disease (NAFLD) - PMID 33963681 Human RCT
Pediatric obesity — weight management in children and adolescents - PMID 35392872 Human RCT
Diabetic kidney disease / nephropathy - PMID 36314246 Human RCT
Visceral and ectopic fat reduction - PMID 37672063 Human RCT
Pediatric obesity — weight management in children and adolescents - PMID 38227621 Human RCT
Stable bipolar disorder with obesity — weight and binge eating - PMID 38782201 Human RCT
Prediabetes — weight and metabolic management - PMID 39904668 Human RCT
Obesity and overweight — weight management - PMID 40276845 Human RCT
Peripheral artery disease — peripheral perfusion improvement in T2DM - PMID 41820778 Human RCT
Obesity and overweight — weight management - PMID 38183597 Human observational
Weight management after bariatric surgery failure - PMID 28479118 Mixed
Polycystic ovary syndrome (PCOS) — metabolic and reproductive outcomes - PMID 37966282 Mixed
Diabetic cardiomyopathy — cardioprotection - PMID 39107809 Mixed
Polycystic ovary syndrome (PCOS) — metabolic and reproductive outcomes - PMID 40471368 Mixed
Depressive symptoms — potential psychiatric application - PMID 40481408 Mixed
Polycystic ovary syndrome (PCOS) — metabolic and reproductive outcomes - PMID 30823403 Animal studies only
Neuroprotection — Alzheimer's disease and cerebral ischemia - PMID 35311455
200 µg/kg/day intraperitoneally intraperitoneal injection (animal) - PMID 35546791
- PMID 36410565 Animal studies only
Opioid use disorder — reduction of heroin/fentanyl seeking in preclinical models - PMID 37310057 Animal studies only
Hepatic steatosis — lipid accumulation reduction - PMID 38548245 Animal studies only
Aortic aneurysm and dissection — protective effects - PMID 39154828
0.4 mg/kg per day Not specified (animal study) (animal) - PMID 39159301 Animal studies only
Diabetic wound healing - PMID 39340991 Animal studies only
Renal ischemia-reperfusion injury — renoprotection - PMID 40332323 In vitro only
Age-related macular degeneration — RPE cytoprotection - PMID 40784419 Animal studies only
Intrauterine adhesion — anti-fibrotic/anti-inflammatory effect